Resistance to thrombomodulin is associated with de novo portal vein thrombosis and low survival in patients with cirrhosis
- 8 February 2016
- journal article
- Published by Wiley in Liver International
- Vol. 36 (9) , 1322-1330
Abstract
Background & Aims: Portal vein thrombosis (PVT) is frequently observed in cirrhosis and may be a clinically important complication. In vitro assays for endogenous thrombin potential (ETP) demonstrated that in cirrhosis plasma has intrinsic resistance to the anticoagulant action of thrombomodulin (TM‐R). This study retrospectively explores the association of TM‐R with de novo PVT and its clinical impact on cirrhosis.Methods: Fifty‐three patients with cirrhosis were tested for ETP‐ratio with/without thrombomodulin. Clinical, endoscopic variables, presence/absence of PVT by Doppler‐US and/or CT examination were collected at baseline and up to 4 years from baseline. The de novo PVT was the primary clinical end‐point. Portal hypertension (PHT)‐related complications and transplantation free survival were secondary end‐points. ETP‐ratio higher than the 95° percentile of the distribution in 173 healthy controls defined TM‐R.Results: During 48 months of follow‐up, 11 patients developed de novo PVT, with preference for the 36 patients with TM‐R after adjusting for Child–Pugh class (HR: 8.354; 90%CI:1.475 ‐ 47.305; P = 0.009). Seventeen patients experienced PHT‐related complications, 23 either died or underwent liver transplantation. PHT complications and transplantation free survival were associated with TM‐R, but were independently predicted by Child–Pugh class, only. Same results were obtained by considering the MELD score.Conclusions: Owing to PVT results from the pro‐coagulant imbalance occurring in patients with advanced cirrhosis, TM‐R might serve as a predictor and could possibly be a biological mediator of adverse outcome in patients with advanced cirrhosis.Keywords
Funding Information
- Italian Ministry of Health
This publication has 36 references indexed in Scilit:
- Efficacy and Safety of Anticoagulation on Patients With Cirrhosis and Portal Vein ThrombosisClinical Gastroenterology and Hepatology, 2012
- The Coagulopathy of Chronic Liver DiseaseNew England Journal of Medicine, 2011
- Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertensionGut, 2011
- Portal vein thrombosis and liver transplant survival benefitLiver Transplantation, 2010
- Detection of the Imbalance of Procoagulant Versus Anticoagulant Factors in Cirrhosis by a Simple Laboratory MethodHepatology, 2010
- Antiphospholipid Antibodies and Antiphospholipid Syndrome: Role in Portal Vein Thrombosis in Patients With and Without Liver CirrhosisClinical and Applied Thrombosis/Hemostasis, 2010
- Systematic review: portal vein thrombosis in cirrhosisAlimentary Pharmacology & Therapeutics, 2010
- Extrahepatic Portal Vein ThrombosisSeminars in Liver Disease, 2008
- Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosisJournal of Hepatology, 2004
- Hepatic and portal vein thrombosis in cirrhosis: Possible role in development of parenchymal extinction and portal hypertensionHepatology, 1995